ReNerve Ltd (ASX:RNV, OTC:RNVEF) has executed a distribution agreement with Swedish Trading Company Limited (STC) to commercialise its NervAlign products across Hong Kong, Macau and the Greater Bay Area.
The agreement follows ReNerve’s recently announced expanded product approval across the jurisdictions and covers a combined addressable population of about 88 million people.
Agreement targets key regional markets
Under the terms of the agreement, STC will manage importation, warehousing, marketing, sales and distribution of ReNerve products across Hong Kong, Macau and the Greater Bay Area.
ReNerve will provide clinical and technical support, training and regulatory liaison.
The agreement is exclusive for an initial three-year term and includes performance milestones and renewal options.
ReNerve and STC are currently shipping the first stocking orders to the Hong Kong region.
Established medical device network
STC is a Hong Kong-based medical device distributor with an established commercial presence across the region.
The company represents complementary international healthcare brands and maintains direct relationships with major hospital and clinical networks.
"Securing a distribution partner of STC's calibre is a significant milestone for ReNerve and a direct result of the expanded regulatory approval we recently received across the region. STC has deep relationships with key clinical networks and hospital systems across the region, and we believe they are the ideal partner to drive rapid and effective market penetration for ReNerve," said Dr Julian Chick, ReNerve CEO.
"The Greater Bay Area of Hong Kong represents one of the most dynamic and well-resourced healthcare markets in Asia, and this agreement positions us to capture meaningful commercial traction in a region where the unmet need in nerve repair is important for ReNerve.. We look forward to working closely with the STC team to bring ReNerve to patients across this region."
Greater Bay Area opportunity
The Guangdong–Hong Kong–Macau Greater Bay Area comprises 11 cities with a combined GDP of about US$2 trillion and a population of more than 88 million people.
ReNerve said the region had seen significant investment in healthcare infrastructure and was recognised as a priority market for innovative medical technologies under China’s national health strategy.
The company is developing products for peripheral nerve injury repair, including its NervAlign nerve repair technologies.
What’s next
With the distribution agreement now executed, ReNerve and STC are moving to supply initial stocking orders into Hong Kong.
The companies will work together on market entry activities, including clinical engagement, surgeon training and commercial rollout across Hong Kong, Macau and the Greater Bay Area.